You are here: Industry Insights > UCB

News List

Amgen, UCB Receives Negative Opinion on EMA Application EVENITY™ in EU americanpharmaceuticalreview
July 01, 2019
Amgen and UCB announced the companies have been informed the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on ...
FDA Clears Nayzilam as First Nasal Spray to Treat Seizure Clusters drugs
June 03, 2019
FDA Clears Nayzilam as First Nasal Spray to Treat Seizure Clusters.
NICE recommends UCB's Cimzia in severe plaque psoriasis pharmafiles
April 23, 2019
NICE has announced its decision to recommend UCB Pharma’s Cimzia (certolizumab pegol) for use on the NHS in England in the treatment of severe plaque psoriasis in patients who have failed to respond to, or are unsuitable for, other systemic treatments.
FDA green lights Amgen and UCB's Evenity in postmenopausal osteoporosis patients pharmafile
April 11, 2019
The FDA has decided to approve Amgen and UCB Pharma’s Evenity (romosozumab-aqqg) for the treatment of postmenopausal osteoporosis patients at high risk of fracture, it has been revealed.
FDA approves Amgen, UCB's postmenopausal osteoporosis drug Evenity firstwordpharma
April 10, 2019
The FDA announced Tuesday that it approved Amgen and partner UCB's Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of fracture.
Cimzia maker UCB takes next step in pregnancy initiative for women with IBD with 'Parenthood Project' campaign fiercepharma
February 24, 2019
Thanks to worries and misconceptions about their health, women with inflammatory bowel disease are up to three times more likely than other women to choose not to have children.
UCB and Epilepsy Society partner to bring targeted treatments pharmaceutical-technology
February 13, 2019
Belgian biopharmaceutical firm UCB has partnered with non-profit Epilepsy Society in the UK to provide targeted treatments for epilepsy patients whose seizures do not respond to existing therapies....
Amgen, UCB Receive Positive Vote from FDA in Favor of EVENITY Approval americanpharmaceuticalreview
January 21, 2019
Amgen and UCB announced strong support from the U.S. Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) for the approval of EVENITY (romosozumab) for ....
Amgen and UCB receive positive vote from FDA Advisory Committee in favor of approval for EVENITY™ (romosozumab) worldpharmanews
January 21, 2019
Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) announced strong support from the U.S. Food and Drug Administration Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) for the approval of EVENITY™* (romosozumab)
UCB to spend £200M to create U.K. R&D hub fiercebiotech
January 02, 2019
UCB is set to spend up to £200 million ($255 million) to create a new R&D facility in the U.K. The British government unveiled UCB’s investment in its second life science sector deal, which disclosed total spending of £1.3 billion.....

Previous page 1 2 3 4 5 6 Next page